Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|January 3, 2020
- Pharmaceutical Technology\'s In the Lab eNewsletter-01-08-2020
- Volume 15
- Issue 1
Micromeritics Instrument Launches the SAS II for Particle Sizing
The device uses the air permeability technique to enhance the productivity and accuracy of particle sizing.
Advertisement
Micromeritics Instrument, a material characterization technology company based in Norcross, GA, announced the launch of the Sub-Sieve Autosizer II (SAS II), a device that enhances the productivity and accuracy of particle sizing via the air permeability technique, on Dec. 3, 2019.
According to a company press release, the autosizer comes equipped with fully automated measurement sequences which include computer-controlled sample compaction and pressure stability for high repeatability. Reports are generated automatically and can be customized to meet company requirements as security features lock down measurement methods and configuration parameters from unofficial changes.
The device handles particle size measurements from 0.2 µm to 75 µm by using the non-destructive air permeability technique to measure the pressure drop across a packed bed of sample at a defined air flow rate, accurately measuring finer powders, according to the release. Additionally, the autosizer functions with specific ASTM standards including E2980, E2651, B330-12, and B330-15 for metal powders and C721-15 for alumina and silica powders.
Source:
Articles in this issue
almost 7 years ago
Ensuring Viral Control in Viral Vector Manufacturingalmost 7 years ago
Understanding Evolving E&L Regulationsalmost 7 years ago
BHP Opens New Elemental Impurities Testing Facilityalmost 7 years ago
CatSci Announces Appointment of New Board Membersalmost 7 years ago
LabTwin Named a Finalist in 2019 Fierce Innovation Awardsalmost 7 years ago
Charles River Partners with Bit Bio for Human Cell Suite ExpansionAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement